Selective MC4 receptor agonist

Plain-language summaryIntrigue 84 / 100

Setmelanotide, sold as Imcivree, is a selective MC4 receptor agonist approved by the FDA for genetic obesity caused by mutations in the leptin-melanocortin pathway. It is one of the first targeted obesity drugs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

63/100

Precision MC4 agonist with clean rare-disease evidence, limited to genetic responder populations

Look, setmelanotide is one of the more elegant precision-medicine stories in obesity research, and we mean that sincerely. The compound targets MC4 receptors in the hypothalamus, sitting downstream of a well-characterized signaling cascade: leptin binds LEPR, activates POMC neurons, which release alpha-MSH, which hits MC4 to suppress appetite and increase energy expenditure. In patients with loss-of-function mutations in POMC, LEPR, or PCSK1, that pathway breaks at one of its upstream nodes. Setmelanotide sidesteps the break entirely, stepping in at MC4 directly. Its roughly 5 nM affinity for MC4 with meaningful selectivity over MC1 and MC3 is what makes it clinically workable – earlier nonselective melanocortin agonists like bremelanotide and melanotan II couldn’t avoid MC1/MC3-related side effects including pigmentation changes and nausea.

The clinical story is solid. The Rhythm Pharmaceuticals pivotal trials in POMC-deficient and LEPR-deficient patients showed 10-13% body weight reduction over roughly one year, effect sizes you genuinely don’t see that often in rare disease work. The Bardet-Biedl syndrome approval followed in 2022, extending the indication to a syndromic ciliopathy where MC4 pathway disruption is one piece of a larger genetic picture. Phase 3 data for both indications hold up to scrutiny – small N, obviously, because the populations are rare by definition, but the effect sizes are large enough that statistical confidence isnt the limiting concern.

Here’s the thing though: that genetic precision is also what limits the score. Outside the defined responder populations, setmelanotide basically doesn’t work. Trials in common polygenic obesity came up essentially empty. So as a research target for investigators exploring obesity broadly, it’s useful mainly as a proof-of-concept that the MC4 pathway is load-bearing in genetically intact humans – which, sure, thats interesting, but the therapeutic utility narrows sharply once you leave rare genetic disease territory. The novelty window closed fast once the pivotal data were published; the mechanism is now well-understood and the approved populations are clearly delineated.

The ongoing expansion into craniopharyngioma-associated hypothalamic obesity and SRC1 haploinsufficiency is worth watching. These are conditions where MC4 pathway disruption happens through tumor damage or partial LOF rather than complete null mutations, and a positive readout in those spaces would meaningfully widen the relevant population. There are active trials as of 2024-2025. Bench value is real but specialized: setmelanotide is an excellent probe for dissecting MC4-dependent appetite suppression from MC4-independent energy expenditure effects, and for delineating downstream hypothalamic effectors in genetic obesity models. For labs actively working on melanocortin pathway biology, we think it’s close to indispensable. For everyone else, the utility is considerably more limited than the approval history might initially suggest.

Novelty: 55
Mechanism promise: 60
In-category differentiation: 68
Evidence quality: 72
Translational signal: 68
Research bench value: 58

Rationale FDA-approved in 2020 and 2022 for genetically defined obesity syndromes with large effect sizes in well-characterized responder populations; the precision of the genetic-responder model is simultaneously its scientific strength and its research ceiling, constraining broader novelty and translational reach outside rare disease territory.

Selective MC4 receptor agonist

An FDA-approved (2020) selective MC4 receptor agonist (Imcivree) for genetic obesity disorders (POMC, LEPR, PCSK1 deficiency).

Abstract

Setmelanotide (Imcivree; RM-493; CAS 920014-72-8; molecular weight 1117.34) is a selective MC4 receptor agonist developed by Rhythm Pharmaceuticals and approved by the FDA in 2020 for chronic weight management in adults and children aged 6 years and older with obesity due to proopiomelanocortin (POMC), leptin receptor (LEPR), or PCSK1 deficiency. The compound is also approved for Bardet-Biedl syndrome obesity (2022). Mechanism is selective MC4 agonism in the hypothalamus, restoring downstream signaling in the leptin-melanocortin pathway disrupted by upstream genetic defects. The drug produces clinically meaningful weight loss in the genetically defined responder populations but minimal effect in non-genetic obesity. Pharmacokinetics: subcutaneous administration daily; plasma half-life approximately 11 hours. Approved doses are 2 to 3 mg once daily.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-094Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Selective MC4 receptor agonist

Setmelanotide

Abstract

Read the full monograph